This is the first report of presumed sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Str€ aussler-Scheinker disease (GSS) with the prion protein gene c.305C>T mutation (p.P102L) occurring in one family. The father and son were affected with GSS and the mother had a rapidly progressive form of CJD. Diagnosis of genetic, variant, and iatrogenic CJD was ruled out based on the mother's clinical history, genetic tests, and biochemical investigations, all of which supported the diagnosis of sCJD. However, given the low incidence of sCJD and GSS, their co-occurrence in one family is extraordinary and challenging. Thus, a hypothesis for the transmission of infectious prion proteins (PrP Sc ) via microchimerism was proposed and investigated. DNA from 15 different brain regions and plasma samples of the CJD patient was subjected to PCR and shallow sequencing for detection of a male sex-determining chromosome Y (chr. Y). However, no trace of chr. Y was found. A long CJD incubation period or presumed small concentrations of chr. Y may explain the obtained results. Further studies of CJD and GSS animal models with controlled genetic and proteomic features are needed to determine whether maternal CJD triggered via microchimerism by a GSS fetus might present a new PrP Sc transmission route.
INTRODUCTION
Creutzfeldt-Jakob disease (CJD) is a rare, transmissible neurodegenerative disease caused by misfolding of the hostencoded prion protein (PrP C ) into its protease-resistant forms (PrP Sc ), which are called prions (1) . Human prion diseases occur in sporadic (80%-95%), genetic (10%-15%), and acquired (<1%) forms (2) .
Prior to the discovery of the prion protein gene (PRNP), genetic prion diseases were classified according to their clinicopathological features as genetic Creutzfeldt-Jakob disease, Gerstmann-Str€ aussler-Scheinker disease (GSS), or fatal familial insomnia (3) . Modern classification of genetic prion diseases is more detailed because missense and nonsense mutations and octapeptide-repeat-insertions and -deletions in the PRNP are well defined (4) .
The most common pathogenic variant in PRNP in GSS cases is a missense mutation, where a single nucleotide substitution (c.305C>T) leads to a replacement of the amino acid proline (P) with leucine (L) at codon position 102 (p.P102L) (3) . The P102L mutation is transmitted autosomal dominantly with complete penetrance, but cases without a family history of neurodegenerative diseases also occur (5) . Moreover, despite the lack of evidence for GSS transmission via blood in humans, GSS transmission has been demonstrated in experiments with apes and rodents that have been inoculated with human GSS brain tissue homogenates or blood (6) (7) (8) (9) .
Iatrogenic CJD (iCJD) is the least prevalent form of CJD, but horizontal human-to-human PrP Sc transmission has been shown via several methods, including contaminated surgical instruments, dura mater and ocular tissue grafts, blood transfusion, treatment with natural growth hormones, and gonadotropin obtained from PrP Sc carriers (10, 11) . Interestingly, there are few reported cases of seemingly etiologically distinct prion dis-eases in one family (12) (13) (14) (15) . Therefore, it is likely that other, yet unidentified, horizontal PrP Sc transmission routes exist. Here, we present the first case of presumed sporadic CJD (sCJD) in a woman who was married to a man with GSS and who had a son with a confirmed P102L mutation causing GSS. To explain this unusual combination of rare prion diseases occurring in one family, we have evaluated the possibility of known transmission routes and investigated a hypothesis of a new PrP Sc transmission route via acquired microchimerism. Microchimerism is a naturally occurring bidirectional exchange of cells between the fetus and mother (16) . The fetus' cells can circulate in the mother's blood or reside in various organs, including the brain, and they can remain there for decades (16) (17) (18) (19) (20) . There is evidence that fetal cells in the mother's body differentiate into multiple cell types, including neurons, to contribute to maternal somatic maintenance (21, 22) .
Because fetal cells can reside in the mother's brain and differentiate into neurons, we hypothesize that if a mother is carrying a fetus with a PRNP P102L mutation, she can be exposed to cells that could cause the development of prion disease. In this situation, P102L-derived PrP Sc in fetal cells would be seeded into the mother's brain, where they would go on to trigger the misfolding of the maternal normal prion proteins (PrP C ).
MATERIALS AND METHODS

Patients and Samples
The family pedigree is shown in Figure 1 , where the CJD patient's husband is denoted as the GSS proband. Clinical information of the CJD patient (III-6), the son with GSS (IV-1), the GSS proband (III-5), and the proband's paternal uncle (II-6) is summarized in Table 1 and described in detail in the Supplementary Material.
Informed consent was obtained from the patients' families. The use of the samples was in accordance with the ethical standards of the Danish ethical committee (De Videnskabsetiske Komiteer Protokol nr.: H-16029969) and with the 1964 Helsinki Declaration and its later amendments.
Half of the CJD patient's brain was pretreated in formic acid, formalin-fixed, and paraffin-embedded (FFPE), and the other half was fresh frozen. For the search of chr. Y in the CJD patient's brain, DNA was extracted from 15 different areas of the frozen half of the brain: frontal lobe, parietal lobe, temporal lobe, occipital lobe, cingulate gyrus, hippocampus, amygdala, caudate nucleus, putamen, globus pallidus, thalamus, medulla, pons, cerebellum, and spinal cord. Cerebrospinal fluid (CSF) and blood samples were obtained while the patient was hospitalized and were made available for the study.
The son is alive, and his blood sample was made available for the study.
Half of the GSS proband's brain was FFPE, and half of it was formic acid pretreated and formalin fixed.
Immunohistochemistry FFPE brain tissues of the CJD patient and GSS proband were cut into 3-mm-thick sections and stained with hematoxylin and eosin (H&E). Immunohistochemistry included staining for glial fibrillary acid protein (1:6400, Dako, Glostrup, Denmark); microglia-CD68 (1:200, Dako); p62 (1:800, Santa Cruz Biotechnology, Dallas, TX); b-amyloid (1:200, Dako); Tau (1:400 Dako); a-synuclein (1:5500, Millipore, Burlington, MA); ubiquitin (1:400, Dako); and protease-K-resistant prion proteins binding 12F10 (1:1500, Dako) and KG9 (1:1000, DiaNova, Hamburg, Germany) antibodies. The conditions used for the 12F10 and KG9 staining are described below.
12F10
The sections were pretreated in a microwave oven with 2 mM hydrogen chloride at 121 C for 8-10 minutes; treated with protease K ([PK] Millipore) for 5 minutes; and stained with 12F10 antibody (Dako) using the Dako autostainer platform. The sections were pretreated in PT Link using a high pH/low pH target retrieval solution (Dako). The staining was conducted on the DakoLink 48 utilizing the EnVision Flexþ detection kit (Dako).
KG9
Before the KG9 was applied, the sections were pretreated with PK. The KG9 staining was performed with the Ventana Benchmark Ultra utilizing the UltraView/Optiview detection kit (Roche Diagnostics, Basel, Switzerland).
DNA Extraction
For the fresh frozen brain tissue, 2 methods were applied for DNA extraction: 1) NucleoSpin Tissue Kit (MachereyNagel, Düren, Germany), and 2) the phenol-chloroform DNA precipitation method, which was also used for FFPE tissues. The latter method is based on samples being deparaffinized with xylene, their subsequent homogenization with a lysis buffer (pH 8.5, 0.5% 20 mM Tris buffer, 0.5% NP-40, sodium deoxycholate) and PK; followed by DNA precipitation with phenol, water, chloroform, and glycogen; and DNA washing with 70% ethanol and RNAse-free water.
DNA from the blood samples was extracted with the QIAamp DNA Blood Midi Kit following the manufacturer's recommendations. DNA from 4 mL plasma was extracted using the QiaSymphony circulating DNA Kit according to the manufacturer's specifications (Qiagen, Hilden, Germany).
PCR and Sequencing
Several short overlapping PCR amplicons covering the coding region of PRNP were designed. Allele-specific primers were designed to identify the allele carrying the P102L-mutation. For P102L detection in PRNP, the son's DNA was extracted from a blood sample and used as a positive control. All primers were designed using NM_183079 (chr20: 4686094-4701590; UCSC Genome Browser, GRCh37/hg19 assembly) as the reference sequence. Primers were designed with the addition of T3 and T7 tails to the forward and reverse primers, respectively, which were later used for the sequencing of the amplified products. The primers used for amplification of the sexdetermining region Y (SRY) have previously been described (23) . All primers used in the current study are shown in Table 2 .
For the PCR reactions, DNA samples were diluted to 10 ng/mL and 100 ng/mL. To validate the SRY detection assay, male and female DNA extracted from the blood samples from patients without neurological pathologies and male and female DNA extracted from fresh frozen CJD brain tissues were included as positive and negative controls, respectively. PCR reactions for the PRNP and SRY coding regions amplification were performed using the following parameters: 94 C for 5 minutes, then the following cycle at 94 C for 30 seconds, 55 C for 30 seconds, 72 C for 1.5 minutes repeated 39 times followed by 72 C for 5 minutes, then stored at 4 C. PCR products were visualized using QIAxcel Advanced equipment together with QIAxcel ScreenGel software, and the PCR products were isolated using the QIAquick PCR purification kit (Qiagen).
For sequencing using the T3 and T7 primers, 25 ng of the purified PCR products was used for BigDye incorporation using the BigDye Terminator 3.1 Cycle Sequencing Kit and was sequenced on an Applied Biosystems ABI3500 Dx Genetic Analyzer in accordance with the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA).
Restriction endonuclease NsP1 analysis was performed to verify polymorphism at codon 129 (methionine/valine) and validate the quality of the DNA. PCR reaction was performed, and PCR products were visualized on 1% agarose gel electrophoresis run with ethidium bromide, as described by Dyrbye et al (24) .
Sequencing libraries were prepared, and shallow sequencing on the Ion Proton platform (Thermo Fisher Scientific) was performed to quantify the amount of high-quality mapping reads (MAPQ ! 80) aligning to chr.Y, as described by Johansen et al (25) .
Real-Time Quaking-Induced Conversion (RT-QuIC)
The CJD patient's CSF sample was delivered to the National Creutzfeldt-Jakob Disease Research and Surveillance Unit in Edinburgh, Scotland for a RT-QuIC analysis, which was previously described by McGuire et al (26) .
Western Blot
Fresh frozen brain tissues were manually homogenized in 2 mL Eppendorf tubes using pestles. The lysis buffer volume and tissue weight ratio was 9:1. One-fortieth volume of 2.0 mg/mL PK (Millipore) was added to supernatants and incubated at 37 C for an hour. PK activity was stopped by adding 1/100 volume of Pefabloc SC (Roche). To ensure the detection of variably protease-sensitive types of CJD, 50 mL of supernatants were centrifuged for 1 hour, and the pellets were resolved in a 15 mL lysis buffer. All supernatant aliquots containing the LDS sample buffer and reducing agent were resolved on a 10% Bis-Tris gel (Thermo Fisher Scientific) for 40 minutes at 200 V. Then, the proteins from the gel were transferred to the PVDF membrane (Bio-Rad, Hercules, CA) and immunoblotted. The monoclonal antibody 3F4 (1:10 000, Millipore) was used as the primary antibody, and Amersham ECL antimouse HRP-conjugated antibody (1:50 000, GE Healthcare, Little Chalfont, United Kingdom) was used as the secondary one. The blots were developed using the Amersham ECL Prime substrate (GE Healthcare) and visualized with VersaDoc, 3000 (Bio-Rad). All procedures were performed in a biosafety level-3 laboratory. For Western blot analysis, fresh frozen CJD type 1, type 2A (Parchi's classification [27, 28] ), and variably protease-sensitive prionopathy (vPSPR) samples were used as controls. The vPSPR control tissue was provided by MRC Edinburgh Brain & Tissue Bank, Scotland.
RESULTS
Clinical History and Findings
The CJD patient's medical records did not state invasive cranial or eye surgeries or treatments, blood transfusions, or FIGURE 1. The pedigree of the family. The GSS proband (III-5), indicated with an arrow, carried the P102L mutation in the PRNP causing GSS (horizontal pattern). The CJD patient (III-6, wife of the proband) is marked with a vertical pattern. The son (IV-1) shares the PRNP P102L mutation and is diagnosed with GSS (horizontal pattern). Many of the proband's paternal family members had motor symptoms and dementia (dotted pattern) that might represent GSS cases. The CJD patient's mother also had dementia (checked pattern). The family members whose mutation status is unknown are indicated with a question mark. PET/MR FDG Whole-body scan was normal; brain scan revealed generally reduced metabolic activity.
Parietotemporally moderately reduced (symmetrically distributed) metabolic activity with involvement of mesial parietal structures; only slight bifrontal affection. detected; amyloid beta 1-42 was decreased; pTau was normal; Tau, 14-3-3 protein and NSE were elevated.
14-3-3 protein and oligoclonal bands were not detected; amyloid beta 1-42, NSE, and pTau parameters were normal; Tau and neurofilament light polypeptides were elevated.
Mononuclear pleocytosis; raised spinal protein.
(continued)
Are skevi ci ut _ e et al J Neuropathol Exp Neurol • Volume 77, Number 8, August 2018 growth hormone and gonadotropin treatments. Therefore, the diagnosis of iCJD gained via known PrP Sc transmission routes could not be supported.
Although the CJD patient did not have a special diet and was consuming a variety of meat and dairy products, the Western blot results do not support the diagnosis of variant CJD, which is caused by consumption of bovine meat infected with PrP Sc that normally is type 2B. Clinical findings in the CJD and GSS patients were not characteristically distinctive. The main differences were observed in the patients' age at disease onset and duration and in the CSF findings. The CJD patient's disease duration was 6 months, while all the GSS patients in the family had a disease duration longer than 4 years. The CJD patient's CSF showed decreased b-amyloid 1-42, elevated Tau, 14-3-3 protein, and NSE, and positive PrP Sc amplification; whereas the son's CSF showed elevated Tau and neurofilament light polypeptide. The son's CSF sample was not used for RT-QuIC analysis.
Neuropathology
Macroscopically, the brain from the GSS proband (III-5) appeared to be normal. Microscopically, spongiform changes were seen throughout the gray matter (Figs. 2a, c, 3e) . The changes were the most noticeable in the neocortex, where the cortical layering was often lost (Fig. 2a, e) . In the striatum, thalamus, and cerebellum, spongiform changes were moderate and differed from area to area. Neuronal loss was severe, and astrogliosis was prominent in the cortex, basal ganglia, and cerebellum. Microgliosis was variable, minimal in the cerebral cortex, and more pronounced in the basal ganglia and cerebellum. In the cerebellum, distinct uni and multicentric plaques were found throughout the molecular layer and in the granular layer (Fig. 3a) , and plaques were also seen in the H&E stain in the cortex and striatum (Figs. 2c, 3e ). 12F10 and KG9 immunostaining demonstrated strong reactions for PrP Sc in both plaques and coarse granular deposits (Figs. 2e, 3c, g ). The pontine nuclei, the inferior olivary nuclei, and the spinal tracts were all unaffected. Throughout the cerebrum and cerebellum, the white matter seemed rarefied although not obviously damaged. In the brain stem, pons, and medulla, the myelin looked quite normal. Few, but very distinct, tau-positive tangles were seen in the hippocampal gyrus. Dots and rod-like ubiquitinpositive structures were found throughout the cerebrum and cerebellum.
Macroscopically, the brain from the CJD patient (III-6) showed a light degree of atrophy, especially in the cerebellum. Microscopically, spongiform changes, neuronal loss, astrogliosis, and microgliosis were seen throughout the gray matter. Prion depositions were found in the immunostains, and microgliosis often followed the same pattern; the changes were the most severe in the limbic structures, striatum, cerebellum, and brainstem nuclei (Fig. 3b, f) . The changes were only focally present in the neocortex (Fig. 2b) . Immunostaining demonstrated strong reactions for both 12F10 and KG9 in a synaptic and perineuronal pattern (Figs. 2d, 3d, h ). In the neocortex, the immunostaining was patchy, but when present, the deposition of PrP Sc often had a linear pattern in layers 4 and 5 (Fig. 2f) . Supplementary staining for ubiquitin, p62, a-synuclein, b-amyloid, and Tau revealed few Tau-positive tangles located only in the transentorhinal cortex. b-Amyloid plaques were seen throughout the neocortex and also in the striatum but not in mesencephalon or cerebellum. CERAD scoring of neuritic plaques was not performed. In conclusion, the level of Alzheimer-related neuropathological changes, according to the ABC classification system, was low (ABC score: A3, B1, Cx) (29) . Furthermore, neither Lewy body nor vascular neuropathological changes were found.
Molecular Genetics
The PCR that was performed with the specific primers needed for SRY detection in the DNA from the CJD patient's brain tissues from 15 different regions did not yield positive results. The shallow sequencing of the CJD patient's plasma indicated 137 high-quality chr.Y reads in 25 302 122 raw reads. However, normally, pregnant women carrying male fetuses present with an average of 938 high-quality chr.Y reads (30) .
The sequencing of the PRNP coding region revealed that the CJD patient (III-6) was homozygous for valine (V) at codon position 129 (c.385G, p.M129V) and had a nonpathogenic silent mutation at codon position 117, which codes for the amino acid alanine (c.351A>G, p.A117A) and is linked to allele coding for V at codon position 129 (Fig. 4a) (24) . V homozygosity at codon 129 was also confirmed by restriction endonuclease NsP1 analysis.
The son (IV-1) is heterozygous for methionine and valine (MV) at codon 129 (c.385A>G, p.M129V). He has a pathogenic missense mutation replacing the amino acid proline with leucine at codon 102 (c.305C>T, p.P102L). The missense mutation is located on the allele, which encodes M at codon position 129 (P102L-129M) because the allele coding for V was mutation-free. He also carries a silent mutation at codon 117 (c.351A>G, p.A117A; Fig. 4b ).
The P102L mutation was also identified in the GSS proband (III-5), but there was no information about this patient's genotype at codons 117 and 129. Therefore, we sought to extract the GSS proband's DNA from FFPE and formalin fixed brain tissues and then amplify and sequence it. However, extraction of a satisfactory quality DNA was not possible because of a long tissue fixation period (since 1999).
Western Blot
Western blot analysis of the samples from the CJD patient's frontal cortex and cerebellum revealed the presence of PrP Sc type 2A according to Parchi's classification system (Fig. 5) .
DISCUSSION
This is the first report of presumed sporadic CJD occurring in a person who married into a GSS family. The estimated prevalence of GSS is in the range of 2-5 per 100 million people worldwide, and the annual mortality rate for sCJD in Denmark is 1.46 per 1 million people (31) . The population of Denmark consists of 5 740 185 individuals, and there are 2 registered GSS cases that belong to the same family. The Danish GSS family is only the thirty-fourth known GSS family in the world (32) . One could assume that the risk for a Danish man with GSS to have a wife or a mother who would develop CJD in her seventies is as high as for any other man. On the basis of the mortality rate for sCJD, and assuming that the incidence of sCJD is the same among married and unmarried people, we could state that 1 man out of 684 932 men has a risk of marrying a woman who would develop CJD. However, in this case, the man a priori had GSS, which means that it would take 1 man out of 684 932 men with GSS for such a pairing to occur. Considering the worldwide rarity of GSS cases, the likelihood for co-occurrence of GSS and sCJD in one family is hence very low and warrants an investigation for the possible transmission of prions routes. Four cases of a random co-occurrence of prion diseases in the same family were reported before (12) (13) (14) (15) . In 3 of those reports, evaluation of the likelihood of prion diseases cooccurrence by chance implies a considerably low probability. For example, the occurrence of sCJD in a husband and wife has been reported in the United States in 1998. In the 15-year surveillance period, the evaluation of the statistical likelihood for a couple in the United States to develop sporadic CJD within 5 years from each other was presented as a 2.1% risk, given the size of the population and its assumed structure at the time (13) . In a case study from Switzerland, the estimated probability for a sibling of an iCJD patient to develop any kind of CJD was 1.4 Â 10
À3
, and the probability that one patient with sporadic fatal insomnia occurs by chance in a fatal familial insomnia family in Italy ranged from 0.78-1.56 Â 10 À4 (14, 15).
In the current study, a thorough neuropathological investigation of the CJD patient's and GSS proband's brain was performed and revealed a classic sCJD type V2 and GSS, respectively (33) . In the CJD patient, the main histopathological findings were a characteristic diffuse synaptic and perineuronal PrP Sc distribution throughout the brain, spongiosis, and neuronal loss, whereas in the GSS proband, the major finding was the presence of uni and multicentric PrP Sc plaques, especially in the cerebellum.
To ensure that the CJD patient was not exposed to known routes of PrP Sc transmission and did not carry pathogenic mutations, her clinical history was studied, the PrP Sc type was defined, and the coding region of her PRNP was sequenced. Neither the clinical history nor the biochemical findings of the CJD patient's tissues provided evidence of iCJD or variant CJD.
No established pathogenic mutations were found in the CJD patient's PRNP coding region. However, she had a silent A117A mutation, which is present in only 5%-10% of the population in Western countries and is considered nonpathogenic because the evidence for its impact on prion diseases pathogenesis is lacking (34) . Yet alanine-to-valine replacement at the same codon position (p.A117V) is known to cause GSS (35, 36) . Whether or not the CJD patient's possession of a sCJD in a Woman Married Into a GSS Family silent A117A mutation in PRNP could have favored the CJD susceptibility in the given GSS family case remains to be elucidated, but if its presence was a cofactor, this could explain the rarity of CJD cases in GSS families. Given the unusual circumstances, we hypothesized that the cells of the fetus, which carried the P102L mutation in PRNP and PrP Sc , might be transmitted to the mother's brain via acquired microchimerism, thus triggering the conversion of maternal PrP C into PrP Sc . The microchimerism would have marked the start of the CJD incubation period. Although more than a 50-year incubation period seems lengthy for sCJD, there were cases of iCJD and Kuru incubation lasting up to 40 and 56 years, respectively, underlining the possible variability of the incubation period of prion diseases (37, 38) .
During pregnancy, both the fetus' and mother's bloodbrain barriers exhibit increased permeability, allowing the exchange of DNA and cells (16) . Microchimerism in female brains has been reported in 63% of all women who carried a male fetus, and it was detectable when measured 2 decades after the pregnancy (16) .
We know that the CJD patient who married into the Danish GSS family was pregnant with the male fetus with GSS 52 years before her death. Therefore, her DNA samples from 15 different brain regions and blood plasma was extracted to search for the male sex-determining chr.Y. However, no male SRY was detected in the maternal brain. Besides, the number of high-quality chr.Y reads in the maternal plasma was too small to conclusively prove the presence of genuine male fetus' cells (30, 39) .
Different factors may have influenced the negative results: 1) the fetus cells might have vanished from the mother's body because of the 52-year period since the putative microchimerism; 2) the sensitivity of the chr.Y detection methods might not have been high enough for the presumed low level of the target Y-sequence; and 3) although the samples were taken from 15 brain regions, it could be possible that the fetal cells were missed (16, 20) . Even though no fetal cells were detected, according to the hypothesis, it is likely that PrP Sc from the fetal cells acted as seeds and started the process of maternal PrP C misfolding and, once triggered, this process could go on for many years, even after the microchimeric fetal cells were lost again.
It is known that CJD susceptibility and phenotypes can differ greatly because of a person's polymorphism at codon 129 in PRNP (40) (41) (42) . In this case, the CJD patient was homozygous for V at codon 129 and had PrP Sc type 2, which is the second most common sporadic CJD type, suggesting that V homozygosity may have favored PrP C misfolding and CJD pathogenesis (35, 43) .
The PrP Sc biochemical and histological picture of the V homozygote CJD patient is very different from that of GSS although, hypothetically, the initial PrP Sc seed was from the P102L-129M GSS fetus. This could be explained by the host PrP Sc strain mutation and/or a strain selection phenomenon, which also might have contributed to the lengthy CJD incubation period.
Strain mutation means that a distinct PrP Sc strain can be propagated on the passage to a new host, even in the same species, if the PrP C primary sequence differs from that of the host.
In humans, the propagation of certain PrP Sc strains is thought to be influenced by variations in the host's PRNP and likely in other genes that shape the microenvironment of the brain too (44, 45 (28, 35, 46) . Moreover, it has been demonstrated that several rodents inoculated with the same human P102L GSS brain homogenate developed distinct pathologies and 2 different PrP Sc strains corresponding to 8 and 21 kDa fragments (47, 48) . Strain selection phenomenon refers to the propagation of one PrP Sc strain over another that is selected by preferential "templating" against the host's PrP C sequence and genetic background (44, 47) . Studies on the transmissibility and conformation of synthetic PrP Sc strains propose that when the host is introduced to a mixture of different PrP Sc strains, those that are the most compatible with the host's PrP C propagate the fastest and dominate the clinical symptoms (49) .
Detailed investigation of the CJD and GSS patients' genomes and proteomes would perhaps reveal more possible explanations for CJD and GSS co-occurrence in one family. However, this would require fresh brain tissues from the GSS proband and the son. Studies of transgenic animal models with genotypes and PrP Sc types corresponding to the Danish GSS and CJD family model could be the next step in resolving the possibility of PrP Sc transmission via microchimerism. Moreover, knowing that the CJD patient's husband was a PrP Sc carrier too, the possibility of other new PrP Sc transmission routes, such as body fluids exchange during sexual relations, should be considered.
In conclusion, the current study is the first report of presumed sCJD and GSS presenting in the same family. We analyzed the clinical, neuropathological, and genetic findings of the affected family members; however, the co-occurrence of such rare diseases in the same family could not be explained by these findings. Thus, we have proposed and investigated a novel possible PrP Sc transmission route in humans. We suggested that via acquired microchimerism, PrP Sc could be freely transmitted from the fetus to the mother and possibly vice versa. Despite the data we have obtained, the time of sampling since the PrP Sc seeding and the overall sensitivity of the genetic measurements necessarily limit the support for our novel transmission hypothesis in this extremely rare Danish case. However, the hypothesis should not be disregarded without further investigation. Exploring new possible prion infection routes and the biological mechanisms favoring them in animal models with controlled genetic and proteomic characteristics would help in elucidating the co-occurrence of CJD and GSS in one family.
The family case presented in the current study, and the 4 other previously reported family cases of rare prion diseases co-occurrence foster the necessity to explore the complexity of possible routes for prions transmission, as well as the biological and environmental factors contributing to the susceptibility of prion diseases. An in-depth comprehension of these aspects of prion diseases is essential for their prevention and for the proper genetic counseling of affected families.
